The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
J Hepatol. 2016 Nov;65(5):879-887. doi: 10.1016/j.jhep.2016.06.025. Epub 2016 Jul 8.
BACKGROUND & AIMS: Delayed hepatitis B virus (HBV) or hepatitis C virus (HCV) diagnosis may increase risk of advanced liver disease complications, including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC). The aim of this study was to characterise "late hepatitis notification" among people with an HBV/HCV notification and advanced liver disease in New South Wales, Australia.
HBV/HCV notifications 1995-2012 were linked to cancer registry and hospital admissions. Late hepatitis notification was defined by a notification after, at the time, or within two years before DC/HCC diagnosis.
HBV and HCV cohorts comprised 50,958 and 79,727 individuals, respectively. Among people with DC (n=3869), late HBV notification declined from 64% (88/138) during 2001-2002 to 31% (46/149) in 2011-2012 (p<0.001), and late HCV notification declined from 52% (179/341) during 2001-2002 to 22% (134/605) in 2011-2012 (p<0.001). Among people with HCC (n=1656), late HBV notification declined from 68% (59/87) during 2001-2002 to 29% (37/128) in 2011-2012 (p<0.001), and late HCV notification declined from 51% (40/79) during 2001-2002 to 17% (49/288) in 2011-2012 (p<0.001).
Despite significant declines in late hepatitis notification since early 2000s, efforts to enhance hepatitis screening, particularly for HBV, are required. Late hepatitis notification as described in this study could be used as a measure of population-level HBV/HCV screening.
Delayed hepatitis B virus (HBV) or hepatitis C virus (HCV) diagnosis may increase the risk of advanced liver disease complications, including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC). The aim of this study was to characterise "late hepatitis notification" among people with an HBV or HCV notification in New South Wales, Australia. Late hepatitis notifications have significantly declined since early 2000s; however, efforts to enhance hepatitis screening, particularly for HBV, are required. Late hepatitis notification as described in this study could be used as a measure of population-level HBV/HCV screening.
延迟的乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）诊断可能会增加晚期肝病并发症的风险，包括失代偿性肝硬化（DC）和肝细胞癌（HCC）。本研究的目的是描述澳大利亚新南威尔士州 HBV/HCV 通知和晚期肝病患者中的“迟发性肝炎通知”。
1995 年至 2012 年的 HBV/HCV 通知与癌症登记处和住院记录相关联。迟发性肝炎通知的定义为在 DC/HCC 诊断后、当时或两年内通知。
HBV 和 HCV 队列分别包括 50958 人和 79727 人。在 DC（n=3869）患者中，迟发性 HBV 通知率从 2001-2002 年的 64%（88/138）下降到 2011-2012 年的 31%（46/149）（p<0.001），迟发性 HCV 通知率从 2001-2002 年的 52%（179/341）下降到 2011-2012 年的 22%（134/605）（p<0.001）。在 HCC（n=1656）患者中，迟发性 HBV 通知率从 2001-2002 年的 68%（59/87）下降到 2011-2012 年的 29%（37/128）（p<0.001），迟发性 HCV 通知率从 2001-2002 年的 51%（40/79）下降到 2011-2012 年的 17%（49/288）（p<0.001）。
尽管自 21 世纪初以来，迟发性肝炎通知率显著下降，但仍需要加强乙型肝炎的肝炎筛查工作。本研究中描述的迟发性肝炎通知可以作为人群 HBV/HCV 筛查的衡量标准。
